公司公告汇总 江苏硕世生物科技股份有限公司于近日收到政府补助人民币163万元，属于与收益相关的政府补助。根 据《企业会计准则第16号－政府补助》的有关规定，该补助将对公司2025年度损益产生一定影响，具体 会计处理及影响金额将以审计机构年度审计确认结果为准。公司董事会保证公告内容真实、准确、完 整。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2025年12月31日收盘，硕世生物(688399)报收于68.5元，下跌1.68%，换手率0.97%，成交量8112.0 手，成交额5603.71万元。 当日关注点 交易信息汇总资金流向 12月31日主力资金净流出775.32万元，占总成交额13.84%；游资资金净流入587.82万元，占总成交额 10.49%；散户资金净流入187.5万元，占总成交额3.35%。 来自交易信息汇总：12月31日主力资金净流出775.32万元，占总成交额13.84%。 来自公司公告汇总：硕世生物近日收到与收益相关的政府补助163万元，预计将对2025年度损益产 生一定影响。 ...

（记者 曾健辉） 每经AI快讯，硕世生物1月4日晚间发布公告称，江苏硕世生物科技股份有限公司于近日收到政府补助 人民币163万元，属于与收益相关的政府补助。 每经头条（nbdtoutiao）——AI泡沫破灭？美股下跌20%？量子计算颠覆加密货币？金价涨破1万美元？ 2026年华尔街和科技圈十大预测来了 ...

证券日报网讯1月4日，硕世生物发布公告称，公司于近日收到政府补助人民币163万元，属于与收益相 关的政府补助。 ...

责任编辑：小讯 财经频道更多独家策划、专家专栏，免费查阅>> 格隆汇1月4日丨硕世生物(688399.SH)公布，江苏硕世生物科技股份有限公司于近日收到政府补助人民 币163万元，属于与收益相关的政府补助。 ...

格隆汇1月4日丨硕世生物(688399.SH)公布，江苏硕世生物科技股份有限公司于近日收到政府补助人民 币163万元，属于与收益相关的政府补助。 ...

证券代码：688399 证券简称：硕世生物 公告编号：2026-001 江苏硕世生物科技股份有限公司 获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 一、获得补助的基本情况 江苏硕世生物科技股份有限公司（以下简称"公司"）于近 日收到政府补助人民币163万元，属于与收益相关的政府补助。 二、补助的类型及其对上市公司的影响 根据《企业会计准则第16号－政府补助》的有关规定，公司 获得的上述政府补助属于与收益相关的政府补助。上述政府补助 未经审计，具体的会计处理及对公司2025年度损益的影响，最终 以审计机构年度审计确认后的结果为准，敬请投资者注意投资风 险。 特此公告。 江苏硕世生物科技股份有限公司董事会 2026 年 1 月 5 日 1 ...

Core Viewpoint - The in vitro diagnostic (IVD) sector is experiencing significant growth, with a notable increase in stock performance among key companies in the industry, driven by strong downstream demand and market expansion [1] Group 1: Market Performance - As of September 22, the IVD sector saw an overall increase of 3.13%, ranking high on the stock performance list [1] - Notable stock performances include: - Bohui Innovation reached a limit-up - Lide Man surged by 11.76% - Shuoshi Biology and Daan Gene increased by 9.17% and 9.01% respectively - Other companies like Dongfang Biology, Shengxiang Biology, Mingde Biology, BGI, Libang Instruments, and Wantai Biology also saw gains exceeding 6% [1] Group 2: Industry Growth - The IVD industry is primarily utilized in hospital laboratories, independent clinical laboratories (ICL), health check centers, epidemic prevention stations, and blood stations [1] - The downstream demand is robust, with IVD growth nearing 20% [1] - In 2018, the revenue from public hospitals for IVD products reached 315.7 billion yuan, with a year-on-year growth rate of 12.48% [1] - Key clients such as ICL and health check centers are also experiencing growth rates around 20% or higher [1] Group 3: Market Size and Comparison - The Chinese IVD industry size reached 71.3 billion yuan in 2018, reflecting a year-on-year growth of 25.6%, significantly outpacing the global IVD market growth of 6.0% [1] - The strong downstream demand is driving rapid growth in the upstream market size [1] - The IVD sector is nurturing large enterprises, and the favorable conditions in specific segments make leading stocks with performance support worth monitoring [1]

证券日报网讯12月25日，硕世生物在互动平台回答投资者提问时表示，公司高度重视国际化战略，积极 推进海外市场布局，加强与国际市场的合作，持续拓展海外业务版图。目前，公司产品已销往全球多个 国家和地区，其中包含欧盟成员国。 ...

Market Overview - The medical device sector increased by 1.35% on December 25, with Sainuo Medical leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] Top Performers - Sainuo Medical (688108) closed at 20.43, up 14.90%, with a trading volume of 609,800 shares and a transaction value of 1.22 billion [1] - Jinhao Medical (920925) closed at 33.03, up 12.81%, with a trading volume of 38,400 shares [1] - Mailland (688273) closed at 40.38, up 12.07%, with a trading volume of 54,800 shares [1] - Tianchen Medical (688013) closed at 52.94, up 11.10%, with a trading volume of 31,200 shares [1] - Xiangyu Medical (688626) closed at 57.47, up 6.80%, with a trading volume of 53,400 shares [1] Underperformers - C Jianxin (688805) closed at 53.31, down 8.28%, with a trading volume of 142,100 shares and a transaction value of 754 million [2] - Tianyi Medical (301097) closed at 51.89, down 5.43%, with a trading volume of 18,800 shares [2] - Hualan Co. (301093) closed at 49.54, down 2.75%, with a trading volume of 39,000 shares [2] Capital Flow - The medical device sector saw a net inflow of 137 million from institutional investors, while retail investors experienced a net inflow of 65.58 million [2] - The sector's main funds saw a net outflow of 203 million from speculative funds [2] Individual Stock Capital Flow - Sainuo Medical had a net inflow of 117 million from main funds, but a net outflow of 98.09 million from retail investors [3] - Zhend Medical (603301) had a net inflow of 85.32 million from main funds, with a net outflow of 76.17 million from retail investors [3] - Huakang Clean (301235) had a net inflow of 65.37 million from main funds, with a net outflow of 64.32 million from retail investors [3]

Core Viewpoint - The company has completed the repurchase and cancellation of shares, reflecting a strategic shift in the use of repurchased shares from employee incentives to cancellation [1] Group 1: Share Repurchase and Cancellation - The company announced the completion of share repurchase and cancellation on December 26, 2025, involving the cancellation of 168,903 shares [1] - The canceled shares represent 0.1715% of the total share capital prior to cancellation, which was 98,499,050 shares [1] - The funds used for this cancellation amounted to 10.9953 million yuan [1] Group 2: Changes in Capital Structure - Following the cancellation, the company's total share capital decreased from 98,499,050 shares to 98,330,147 shares [1] - The registered capital was adjusted from 98,499,050 yuan to 98,330,147 yuan as a result of the share cancellation [1] - The company plans to proceed with the necessary business registration changes following this cancellation [1]